ARTICLE | Clinical News
Xyotax poliglumex paclitaxel: Phase II data
May 23, 2005 7:00 AM UTC
In a Phase II trial in 82 patients, Xyotax plus carboplatin led to a major tumor response in 80 patients (98%) patients based on CA125 levels during the induction phase of the therapy. The data showe...